Statistics for Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial
Total visits
| views | |
|---|---|
| Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial | 0 |
Total visits per month
| views | |
|---|---|
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:310b453e-28da-4690-be4b-397010669bf4 | 83 |
| java.util.UUID:305ce743-bd5b-41e1-9b77-28ccbac8d8f6 | 28 |
| java.util.UUID:e84e48fc-7186-4dc2-b5fd-c1cd73804728 | 13 |
| Wagemann2024Downstream-CCBY.pdf | 12 |